var data={"title":"Omacetaxine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Omacetaxine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/526570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=omacetaxine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Omacetaxine: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15592818\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Synribo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15512860\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Cephalotaxine;</li>\n      <li>\n        Antineoplastic Agent, Protein Synthesis Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515971\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic myeloid leukemia (CML), chronic or accelerated phase:</b> SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Induction:</i> 1.25 mg/m<sup>2</sup> twice daily for 14 consecutive days of a 28-day treatment cycle; continue until hematologic response is achieved</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Maintenance:</i> 1.25 mg/m<sup>2</sup> twice daily for 7 consecutive days of a 28-day treatment cycle; continue until no longer achieving clinical treatment benefit</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> If a dose is missed, skip that dose and resume with the next regularly scheduled dose. Do not administer 2 doses at the same time to make up for a missed dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515972\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515974\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Based on the minimal amount of unchanged drug excreted in the urine, dosage adjustment is not likely necessary (Nemunaitis 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515975\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515973\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Hematologic toxicity:</b>  May delay treatment cycles and/or reduce the number of treatment days during a cycle for hematologic toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Neutropenia grade 4 (ANC &lt;500/mm<sup>3</sup>) or thrombocytopenia &ge; grade 3 (platelets &lt;50,000/mm<sup>3</sup>) during a cycle: Delay the start of the next cycle until ANC &ge;1000/mm<sup>3</sup> and platelets &ge;50,000/mm<sup>3</sup> <b>AND</b> reduce the number of treatment days by 2 days (eg, reduce from 14 days to 12 days or reduce from 7 days to 5 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Nonhematologic toxicity:</b> Manage symptomatically; interrupt and/or delay treatment until toxicity resolves.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15593679\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous, as mepesuccinate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synribo: 3.5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515929\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24794025\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM396919.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WI9o10HNXFe0RtsTqpEN6Uw==&amp;TOPIC_ID=87038\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM396919.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515976\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer subcutaneously at approximately 12 hour intervals. If home administration is to occur, advise patient on proper handling, storage conditions, administration, disposal, and clean-up of accidental spillage; ensure that the patient or patient&rsquo;s caregiver is an appropriate candidate for home administration. Avoid skin and eye contact; wear protective eyewear and gloves during handling and administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132767\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15512862\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic myeloid leukemia:</b> Treatment of chronic or accelerated phase chronic myeloid leukemia (CML) in adult patients resistant and/or intolerant to 2 or more tyrosine kinase inhibitors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515928\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515924\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (29% to 31%), headache (13% to 20%), chills (13%), insomnia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (15%), skin rash (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased uric acid (grades 3/4: 56% to 57%), hyperglycemia (grades 3/4: 10% to 15%; hyperosmolar nonketotic hyperglycemia &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (35% to 41%), nausea (29% to 35%), abdominal pain (16% to 23%), vomiting (12% to 15%), constipation (14%), anorexia (10% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (58% to 76%; grades 3/4: 49% to 88%), neutropenia (20% to 53%; grades 3/4: 18% to 81%), anemia (51% to 61%; grades 3/4: 36% to 80%), leukocyte disorder (decreased: grades 3/4: 61% to 72%), febrile neutropenia (10% to 20%; grades 3/4: 10% to 16%), lymphocytopenia (17%; grades 3/4: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (46% to 56%; grades 3/4: 11% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (22% to 35%; includes edema, erythema, hematoma, hemorrhage, hypersensitivity, induration, inflammation, infusion related reaction, irritation, mass, pruritus, rash)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (23% to 24%), arthralgia (19%), limb pain (11% to 13%), back pain (12%), myalgia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (grades 3/4: 9% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (11% to 17%), cough (&le;16%), dyspnea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (25% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Acute coronary syndrome, angina pectoris, bradycardia, cardiac arrhythmia, chest pain, edema, hypertension, hypotension, palpitations, tachycardia, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Agitation, anxiety, cerebral hemorrhage, confusion, depression, dizziness, hyperthermia, hypoesthesia, lethargy, malaise, mental status changes, mouth pain, myasthenia, pain, paresthesia, sciatica, seizure, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Burning sensation of skin, dermal ulcer, desquamation, erythema, hyperhidrosis, hyperpigmentation, night sweats, pruritus, skin lesion, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased serum glucose (grades 3/4: 6% to 8%), dehydration, diabetes mellitus, gout, hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention, anal fissure, aphthous stomatitis, decreased appetite, dysgeusia, dyspepsia, dysphagia, gastritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gingival hemorrhage, gingival pain, gingivitis, hemorrhoids, melena, mucosal inflammation, oral mucosa ulcer, stomatitis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow failure (10%; grades 3/4: 10%), bruise, hematoma, hemorrhage (ear), oral hemorrhage, petechia, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (grades 3/4: 6% to 9%), increased serum ALT (grades 3/4: 2% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction, transfusion reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm, musculoskeletal chest pain, musculoskeletal pain (or discomfort), ostealgia, stiffness, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, cataract, conjunctival hemorrhage, conjunctivitis, diplopia, eyelid edema, eye pain, increased lacrimation, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms, hemoptysis, nasal congestion, pharyngolaryngeal pain, rales, rhinorrhea, sinus congestion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515933\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515934\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Grade 3/4 neutropenia, thrombocytopenia and anemia commonly occur; generally reversible, although may require treatment delay and/or a reduction in the number of treatment days with future cycles. Myelosuppression may rarely be fatal. Monitor blood counts (in induction and maintenance cycles). Neutropenia may increase the risk for infection. Thrombocytopenia may increase the risk of bleeding; cerebrovascular hemorrhages have been reported (some fatal); gastrointestinal hemorrhages have occurred. Due to the increased risk of bleeding, avoid the use of anticoagulants, aspirin, and NSAIDs when the platelet count is &lt;50,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose intolerance: Omacetaxine may induce glucose intolerance. Hyperglycemia (including grade 3 and 4 events) has been observed; hyperosmolar nonketotic hyperglycemia has been reported (case report). Monitor blood glucose frequently, especially in patients with diabetes or with risk factors for diabetes. Avoid use in patients with poorly controlled diabetes; may initiate after glycemic control has been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &ge;65 years of age are more likely to experience toxicity, especially hematologic toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15517163\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15517161\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87038&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: May enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15516380\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515930\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies at doses less than the equivalent human dose (based on BSA). Based on the mechanism of action, omacetaxine may cause fetal harm if administered during pregnancy. Women of reproductive potential should avoid pregnancy during therapy. Omacetaxine may impair fertility in males.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515932\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if omacetaxine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the decision to discontinue omacetaxine or to discontinue breastfeeding should take into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515979\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (weekly during induction and initial maintenance cycles, then every 2 weeks or as clinically indicated after initial maintenance cycles); blood glucose (frequently); signs/symptoms of infection; signs of bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515958\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Omacetaxine is a reversible protein synthesis inhibitor which binds to the A-site cleft of the ribosomal subunit to interfere with chain elongation and inhibit protein synthesis. It acts independently of BCR-ABL1 kinase-binding activity, and has demonstrated activity against tyrosine kinase inhibitor-resistant BCR-ABL mutations. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15515960\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic phase CML: Mean time to major cytogenetic response: 3.5 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Accelerated phase CML: Mean time to response: 2.3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic phase CML: Median duration of major cytogenetic response: 12.5 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Accelerated phase CML: Median duration of major hematologic response: 4.7 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Rapid (Nemunaitis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 141 &plusmn; 93.4 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &le;50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hydrolyzed by plasma esterases to 4&rsquo;-DMHHT; minimal hepatic metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 14.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: SubQ: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~37); feces (~44%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570459\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Synribo Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5 mg (1): $1,200.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49939775\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Chuan Shan Ning (CN);</li>\n      <li>Fu Er (CN);</li>\n      <li>Gao Rui Te (CN);</li>\n      <li>Hua Pu Le (CN);</li>\n      <li>Jin Nuo Xing (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cortes J, Digumarti R, Parikh PM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. <i>Am J Hem.</i> 2013;88(5):350-354.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/23468307/pubmed\" target=\"_blank\" id=\"23468307\">23468307</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes JE, Kantarjian HM, Rea D, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. <i>Cancer</i>. 2015;121(10):1637-1644.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/25586015/pubmed\" target=\"_blank\" id=\"25586015\">25586015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes J, Lipton JH, Rea D, et al, &ldquo;Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation,&rdquo; <i>Blood</i>, 2012, 120(13):2573-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/22896000/pubmed\" target=\"_blank\" id=\"22896000\">22896000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes JE, Nicolini FE, Wetzler M, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. <i>Clin Lymphoma Myeloma Leuk</i>. 2013;13(5):584-591.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/23787123/pubmed\" target=\"_blank\" id=\"23787123\">23787123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coude MM, Luycx O, Cariou ME, et al, &ldquo;Undetectable Molecular Residual Disease After Omacetaxine and Nilotinib Combination Therapy in an Imatinib-Resistant Chronic Myeloid Leukaemia Patient Harbouring the BCR-ABL1 T315I Gatekeeper Mutation,&rdquo; <i>Br J Haematol</i>, 2012, 157(3):407-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/22225474/pubmed\" target=\"_blank\" id=\"22225474\">22225474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klag T, H&auml;rtel N, Erben P, et al, &ldquo;Omacetaxine Mepesuccinate Prevents Cytokine-Dependent Resistance to Nilotinib <i>in vitro</i>: Potential Role of the Common &Beta;-Subunit C of Cytokine Receptors,&rdquo; <i>Leukemia</i>, 2012, 26(6):1321-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/22289991/pubmed\" target=\"_blank\" id=\"22289991\">22289991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nemunaitis J, Mita A, Stephenson J, et al, &ldquo;Pharmacokinetic Study of Omacetaxine Mepesuccinate Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2013, 71(1):35-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/23053254/pubmed\" target=\"_blank\" id=\"23053254\">23053254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quint&aacute;s-Cardama A, Kantarjian H, and Cortes J, &ldquo;Homoharringtonine, Omacetaxine Mepesuccinate, and Chronic Myeloid Leukemia Circa 2009,&rdquo; <i>Cancer</i>, 2009, 115(23):5382-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omacetaxine-drug-information/abstract-text/19739234/pubmed\" target=\"_blank\" id=\"19739234\">19739234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synribo (omacetaxine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87038 Version 86.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15592818\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F15512860\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15515971\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15515972\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15515974\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15515975\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F15515973\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15593679\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F15515929\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F24794025\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15515976\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132767\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15512862\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15515928\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15515924\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15515933\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15515934\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F15517163\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15517161\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F15516380\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F15515930\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15515932\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15515979\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15515958\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15515960\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570459\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49939775\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/87038|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=omacetaxine-patient-drug-information\" class=\"drug drug_patient\">Omacetaxine: Patient drug information \t</a></li></ul></div></div>","javascript":null}